Krystal Biotech, Inc. — Director's Dealing 2022

Jul 1, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Krystal Biotech, Inc. (KRYS)
CIK: 0001711279
Period of Report: 2022-06-30

Reporting Person: ROSSI DINO A (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-06-30	Stock Option (Right to Buy)	$65.66	A	6800	Acquired	2032-06-30	Common Stock (6800.0)	Direct

Footnotes

F1: The options were awarded on June 30, 2022 and vest in equal monthly tranches over a one-year period.